For three decades, our faculty have engaged in innovative research and clinical efforts to develop novel treatments for opioid-use disorder. Our work began with the seminal studies demonstrating buprenorphine (BUP) treatment efficacy, which contributed to its FDA approval.
Stacey Sigmon, PhD
Director UVM CORA, Associate Professor of Psychiatry, UVM Larner College of Medicine
Best Practices Core
Gail Rose, PhD
Director, Best Practices Core, Assistant Professor of Psychiatry, UVM Larner College of Medicine
Education & Outreach Core
Stephen Higgins, PhD
Co-Director, Education & Outreach Core, Vice Chair of Psychiatry, Director of Vermont Center on Behavior and Health
Surveillance & Evaluation Core
Andrea Villanti, PhD, MPH
Co-Director, Surveillance & Evaluation Core, Associate Professor of Psychiatry, UVM Larner College of Medicine
Nathaniel Schafrick, M.S., M.P.H.
Data Analyst, Surveillance & Evaluation Core
Clinician Advisory Board
Robert Althoff, MD, PhD
Associate Professor of Psychiatry, Pediatrics, and Psychological Sciences, UVM Larner College of Medicine
Brady Heward, MD
Co-Director of Clinical Affairs, Assistant Professor of Psychiatry, UVM Larner College of Medicine
This publication is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $10,365,921 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or the U.S. Government.